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Abbreviations 
AF: atrial fibrillation 
BITA: bilateral internal thoracic artery  
BMI: body mass index 
CCS: Canadian Cardiovascular Society  
CVA: cerebrovascular event  
COPD: chronic obstructive pulmonary disease;  
DM: diabetes 
IR: incomplete revascularization 
IABP intra-aortic balloon pump 
LMD: left main disease 
LVEF: left ventricular ejection fraction 
MI: myocardial infarction 
OPCAB: off-pump coronary artery bypass  
ONCAB: on-pump coronary artery bypass  
PCI: percutaneous coronary intervention  
PVD: peripheral vascular disease  
RRT: renal replacement therapy 
sCr: serum creatinine 
TVD: three vessel disease 
PSM: propensity score matching  
SDM: standardized mean difference   
  
 
Central message 
Off-pump bypass surgery is a safe and feasible option for diabetic patients with 
multivessel disease, it reduces the incidence of early complications and provides 
long term survival benefit similar to on-pump surgery   
  
 
Perspective statement  
Off-pump bypass surgery remains valid option for diabetic patients with multivessel 
disease as it reduces the incidence of early complications and provides long term 
survival benefit similar to on-pump surgery. Its use should not be discouraged in 
such a high risk subgroup.    
  
 
Abstract 
Objective(s): We conducted a single centre analysis on short-term outcomes and long 
term survival in actively treated diabetic patients undergoing off pump coronary artery 
bypass (OPCAB) versus on pump coronary artery bypass (OPCAB) surgery.  
Methods: The final population consisted of 2450 patients with actively treated 
diabetes (mean age 66±9 years; F/M 545/1905, 22%). Of those, 1493 subjects were 
orally treated and 1011 were on insulin. OPCAB and ONCAB were performed in 1253 
and 1197 patients respectively. Propensity score matching was used to compare the 
two matched groups.  
Results: When compared to ONCAB, OPCAB was significantly associated with a 
significant risk reduction for postoperative cerebrovascular accident (OR 0.49; 95%CI 
0.25-0.99; P=0.04), need for postoperative IABP (OR 0.48; 95%CI 0.30-0.77; 
P=0.002) and re-exploration for bleeding (OR 0.55; 95%CI 0.33-0.94; P=0.02). 
OPACB did not significantly affect early (HR 1.32; 95%CI 0.73-2.40; P=0.36) and late 
mortality (HR 1.08;95%CI 0.92-1.28; P=0.32). However, OPCAB with incomplete 
revascularization was associated with a reduced survival rate when compared to 
OPCAB with complete revascularization (HR 1.82; 95%CI 1.34-2.46; P=0.0002) and 
ONCAB with complete revascularization (HR 1.83; 95%CI1.36-2.47; P<0.0001). 
Conclusions: OPCAB is a safe and feasible option for diabetic patients with 
multivessel disease, it reduces the incidence of early complications including 
postoperative cerebrovascular events and provides excellent long term survival similar 
to ONCAB surgery in case of complete revascularization.  
Word count: 219  
  
 
Diabetes mellitus (DM) is a major public health and economic problem with a dramatic 
increase in prevalence and incidence [1]. Coronary heart disease is highly prevalent 
and is the major cause of morbidity and mortality among diabetic patients [2]. Patients 
with DM account for approximately one quarter of all patients who undergo coronary 
revascularization procedures each year [3]. Coronary artery bypass graft (CABG) 
surgery when compared with percutaneous coronary intervention (PCI) has been 
shown to be associated with better outcomes in patients with diabetes [4], and current 
clinical guidelines recommend CABG as the preferred revascularization strategy in 
diabetic patients with complex coronary artery disease [5]. However, DM has a 
significant negative impact on the clinical outcome of coronary surgery in the long term 
as well as in the short term [6]. The debate on the effectiveness or otherwise of off 
pump coronary artery bypass (OPCAB) versus on pump coronary artery bypass 
(ONCAB) surgery continues [7-9]. In particular the role of OPCAB in the management 
of diabetic patients remains controversial as comparative data are scarce and 
inconclusive [10-13]. A recent sub-analysis of the Bypass Angioplasty 
Revascularization Investigation 2 Diabetes trial [10] suggested that patients with 
diabetes had greater risk of major cardiovascular long-term events after OPCAB than 
after ONCAB. However, this study presented several limitations including very small 
sample size and definitive conclusions could not be drawn [14]. In this study, we used 
a large consecutive cohort with DM operated over a 20 years period at a single 
institution, to perform a propensity score matching (PSM) analysis of ONCAB versus 
OPCAB on short-term outcomes and long term survival.  
Methods 
The study was conducted in accordance with the principles of the Declaration of 
Helsinki. The local audit committee approved the study, and the requirement for 
  
 
individual patient consent was waived. We retrospectively analysed prospectively 
collected data from The National Institute for Cardiovascular Outcomes Research 
(NICOR) NACSA registry for all isolated first time CABG procedures performed at the 
Bristol Heart Institute, Bristol United Kingdom from April 1996 to April 
2015.  Reproducible cleaning algorithms were applied to the database, which are 
regularly updated as required. Briefly, duplicate records and non-adult cardiac surgery 
entries were removed; transcriptional discrepancies harmonized; and clinical conflicts 
and extreme values corrected or removed. The data are returned regularly to the local 
units for validation.  
Further details and definition of variables are available at 
http://www.ucl.ac.uk/nicor/audits/adultcardiac/datasets. Among 15119 isolated first 
time CABG cases performed during the study period, we selected subjects who met 
the following criteria: patient with actively treated DM at the time of surgery; multivessel 
coronary disease; data regarding the surgical strategy adopted (OPCAB versus 
ONCAB) was available. Patients with no diabetes (n=12439), single vessel disease 
(n=121) and no data regarding surgical strategy adopted (n=109) were excluded. The 
final population consisted of 2450 patients with actively treated diabetes (mean age 
66±9 years; F/M 545/1905, 22%). Of those, 1493 subjects were orally treated and 
1011 were on insulin. OPCAB and ONCAB were performed in 1253 and 1197 patients 
respectively (Figure 1). In the present series OPCAB was performed according to 
surgeon preference and not based on specific clinical indications (Video 1). 
Normothermic blood cardioplegia was the standard strategy for ONCAB cases during 
the study period. Blood glucose level was strictly maintained at less than 11.1 mmol/L 
perioperatively using insulin infusion and postoperatively for both OPCAB and ONCAB 
procedures.  
  
 
 
Pre-treatment variables and study end-points  
The effect of OPCAB over ONCAB was adjusted for the following variables including: 
age, gender, body mass index (BMI); previous myocardial infarction (MI) within 30 
days, previous percutaneous coronary intervention (PCI); diabetes mellitus (DM) on 
insulin; chronic obstructive pulmonary disease (COPD); Canadian Cardiovascular 
Society (CCS) class III or IV; New York Heart Association (NYHA) class III or IV; 
current smoking; serum creatinine ≥200 mmol/l, previous cerebrovascular accident 
(CVA); peripheral vascular disease (PVD); preoperative atrial fibrillation (AF); left main 
disease (LMD); three vessel disease (TVD); left ventricle ejection fraction (LVEF) 
≤49% and ≤30%,  pre-operative use of intra-aortic balloon pump (IABP), non-elective 
admission, emergent/salvage operation, cardiogenic shock and year of operation. 
Overall risk profile was evaluated by using additive and logistic Euroscore. Incomplete 
revascularization (IR) was defined as at least one diseased primary arterial territory 
not grafted. 
Short term outcomes investigated were postoperative complications including CVA, 
need for IABP defined as unplanned insertion of IABP intraoperatively or 
postoperatively due to hemodynamic instability or for weaning from cardiopulmonary 
bypass, re-exploration for bleeding, renal replacement therapy (RRT), sternal wound 
reconstruction as single and combined end-points and mortality within 30 days. Long 
term outcome was all-cause mortality. All-cause mortality is the most robust and 
unbiased index because no adjudication is required; thus, inaccurate or biased 
documentation or clinical assessments are avoided [15]. Information about death was 
obtained from the institutional database and the National General Register Office for 
  
 
all patients. Data regarding postoperative complications and survival were available 
for all patients (100%) included. 
Statistical analysis 
For baseline characteristics, variables are summarized as mean for continuous 
variables and proportion for categorical variables. Multiple imputation using 
bootstrapping-based expectation-maximization algorithm and including all pre-
treatment variables (Amelia R package, http://www.jstatsoft.org/v45/i07/) was used to 
address missing data (Supplementary Table 1 and Supplementary Figure 1). To 
control for measured potential confounders in the data set, a propensity score (PS) 
was generated for each patient from a multivariable logistic regression model based 
on pre-treatment covariates as independent variables with treatment type (OPCAB vs 
ONCAB) as a binary dependent variable [16]. The resulting propensity score 
represented the probability of a patient to undergo OPCAB (Area under the curve 0.63, 
Supplementary Figure 2). Pairs of patients receiving OPCAB and ONCAB were 
derived using greedy 1:1 matching with a calliper of width of 0.2 standard deviation of 
the logit of the PS (non-random R package, 
http://CRAN.Rproject.org/package=nonrandom). The quality of the match was 
assessed by comparing selected pre-treatment variables in propensity score– 
matched patient using the standardized mean difference (SMD), by which an absolute 
standardized difference of greater than 10% is suggested to represent meaningful 
covariate imbalance [16]. Analytic methods for the estimation of the treatment effect 
in the matched sample included McNemar’s to compare proportions [16]. Time-
segmented Cox regression models (within 30 days and beyond 30 days) [17] that 
stratified on the matched pairs [18] were used to investigate the effect of treatment 
(ONCAB vs ONCAB) on early and late mortality. This approach accounts for the 
  
 
within-pair homogeneity by allowing the baseline hazard function to vary across 
matched sets (survival R package, http://CRAN.R-project.org/package=survival). 
Lastly a multivariate adjustment for all baseline characteristics and intraoperative 
variables such as the use of bilateral internal thoracic arteries (BITAs), the use of the 
Radial Artery (RA) and the incidence of incomplete revascularization was performed 
in the matched sample to correct the effect of OPCAB for residual imbalance (double 
robust) and to estimate the effect size of other covariates on all outcomes investigated. 
Person correlation coefficient and variance inflation factors (VIF) from the covariance 
matrix of parameter estimates was used to assess collinearity in multivariate models 
(usdm R package, http://CRAN.R-project.org/package=usdm). Variables with VIF 
higher than 4 were excluded from multivariate analyses. All p-values <0.05 were 
considered to indicate statistical significance. All statistical analysis was performed 
using R Statistical Software (version 3.2.3; R Foundation for Statistical Computing, 
Vienna, Austria). 
Results 
Pre-treatment variables distribution in OPCAB and ONCAB groups are summarized in 
Table 1. Patients undergoing ONCAB were likely to have CCS III/IV, three vessel 
disease, LVEF≤30% and cardiogenic shock. Era of surgery was also different between 
the two groups. Additive Euroscore (P=0.02) but not logistic Euroscore (P=0.15) was 
higher in the ONCAB group. PSM created a total of 995 pairs perfectly matched for all 
pre-treatment variables (SMD<0.10) including era of surgery. In the matched 
population additive Euroscore (P=0.08) and logistic Euroscore (P=0.12) were 
comparable between the two groups.  
Intraoperative data 
  
 
Table 2 summarizes intraoperative data. When compared to ONCAB, OPCAB was 
associated with a lower number of grafts per patient (2.7±0.7 versus 3.0±0.7 P<0.001; 
Figure 2) in all but left anterior descending artery territories. The rate of bilateral 
internal thoracic artery grafting was particular low in both groups (P=0.1). The use of 
the radial artery was higher in the OPCAB group while saphenous vein graft was more 
frequently used in the ONCAB group.   OPCAB conversion rate was 7/1253 (0.6%).    
Effect of OPCAB on short term outcomes 
Short term outcomes are summarized in Table 3. OPCAB was associated with a 
higher rate of IR. However, when compared to ONCAB, OPCAB was significantly 
associated with 50% relative risk reduction for postoperative CVA (P=0.04), need for 
postoperative IABP (P=0.002) and re-exploration for bleeding (P=0.02). Overall 
mortality within 30 days was 2.4% (58 pts) without significant difference between the 
two groups. This trend toward a benefit from OPCAB on short term outcomes was 
confirmed when results were analysed separately for patients on oral treatment and 
on insulin (Supplementary Table 2 and 3). Among seven OPCAB cases which required 
conversion to ONCAB, no deaths within 30 days were recorded.    
Effect of OPCAB on long term mortality 
At a mean follow-up time of 6.5±4.5 years, there were 357 and 408 deaths in the 
unmatched population and 284 and 299 deaths in the matched sample in the OPCAB 
and ONCAB groups respectively (Figure 2). In the matched sample survival probability 
at 5 and 10 was 82.6±1.2% and 62.6±2.0% and versus 84.3±1.3% and 64.0±1.9% in 
the OPCAB and ONCAB group respectively. The two strategies were perfectly 
comparable in terms of late mortality in the overall matched sample (HR 1.08;95%CI 
0.92-1.28; P=0.32) and among patients orally treated (HR 1.06;95%CI0.85-1.33; 
P=0.6) and on insulin (HR 1.12; 95%CI 0.88-1.43; P=0.35, Figure 3).  
  
 
OPCAB with complete revascularization showed comparable survival when compared 
to ONCAB with complete revascularization (n=921) (HR 1.00; 95%CI 0.84-1.20; 
P=0.96).   OPCAB patients with IR (n=139) showed reduced survival rate when 
compared to OPCAB with complete revascularization (n=856) (HR 1.82; 95%CI 1.34-
2.46; P=0.0002) and ONCAB with complete revascularization (HR 1.83; 95%CI1.36-
2.47; P<0.0001; Figure 4). We could not draw conclusion on the impact on IR among 
ONCAB subjects due to their small sample size (n=74).  
Effect of OPCAB over ONCAB after full adjustment (double robust) 
After double robust adjustment. OPCAB was confirmed to be significantly associated 
with a reduced incidence of postoperative stroke, need for postoperative IABP, sternal 
wound reconstruction, re-exploration for bleeding but not dialysis. OPACB was 
significantly associated with a 2-fold increased risk of incomplete revascularization. 
OPACB was not associated with increased early (within 30 days) and late mortality 
(Supplementary Table 4, central picture).  
Impact of other predictors of outcomes 
Impact of other predictors on outcomes of interest is reported in Supplementary Tables 
5 to 13. In particular, diabetes on insulin was significantly associated with increased 
risk of postoperative dialysis and incidence of any complication. Diabetes on insulin 
did not significantly affect early mortality but was associated with 18% relative risk 
increase in late mortality. IR did not significantly influence operative outcomes and 
early mortality. However, it was associated with nearly 50% relative risk increase in 
late mortality. All variables investigated showed VIF < 4 (Supplementary Table 14).   
Discussion 
To the best of our knowledge this is the largest series with the longest follow-up on the 
impact of OPCAB in patients with actively treated diabetes with multivessel coronary 
  
 
disease. We found that OPCAB was associated with a trend towards a lower incidence 
of postoperative complications including postoperative cardiovascular accidents. 
OPCAB showed comparable early and late survival when compared to ONCAB. The 
present analysis confirmed that OPCAB was associated with a ~7% absolute risk 
increase in incomplete revascularization and OPCAB with IR showed a lower survival 
rate when compared to OPCAB and ONCAB with complete revascularization. Insulin 
treatment was confirmed to be an independent risk factor for postoperative 
complications in particular need for renal replacement therapy and was associated 
with poorer long term survival.   
Despite  several  randomized controlled trials there is still controversy with respect to  
the advantages and disadvantages of OPCAB vs OPCAB surgery [7-9,19,20 ], 
However, some evidence has suggested a potential off-pump benefit for high 
operative risk patient subgroups [21-23]. In the case of diabetic patients with 
multivessel disease only limited data are available with conflicting reports [10-13]. A 
recent observational sub-analysis of the BARI 2D trial [10] concluded that patients with 
diabetes had greater risk of major long-term cardiovascular events after OPCAB than 
after ONCAB. However, this study has been criticized [14] due to the small number of 
patients compared (153 propensity matched pairs) which is inadequate to draw final 
conclusions. Moreover there was missing information regarding the completeness of 
revascularization. A sub-analysis of the ROOBY trial [11] on diabetic patients 
randomized to OPCAB (n=402) or ONCAB (n=433) concluded that 1-year graft 
patency rate was lower after OPCAB with no difference in the 1-year primary 
composite outcome. However, it is largely recognized that in the ROOBY Trial, 
surgeons were inexperienced (on average performing eight OPCAB operations per 
year and with a high conversion rate of around 12% [14]. The importance of surgeon 
  
 
experience in OPCAB is clearly demonstrated in trials that showed no difference in 
hard clinical end-points at 1 year or at longer follow up [7,8,24]. Moreover, the 1% 
lower graft patency rate reported in the OPCAB group is clearly marginal (83.1% vs 
88.4%) and it is likely not to have any clinical impact. On the other hand, Emmert et 
al. [12] compared short term outcomes in 540 OPCAB and 475 ONCAB diabetic 
patients, and showed a clear trend to reduced major complications such as stroke, re-
thoracotomy for bleeding, and postoperative IABP requirement, confirming the 
beneficial effect of OPCAB on short term outcomes in this subset of patients. Renner 
et al. [13] compared 355 OPCAB and 502 ONCAB procedure and they concluded that 
OPCAB was associated with a significant lower 30-day mortality risk and also with a 
lower 1 year mortality risk compared with ONCAB.  
In the present analysis, IR occurred in 15.2% and 7.9% of unmatched OPCAB and 
ONCAB groups respectively. Although patients undergoing OPCAB with complete 
revascularization showed survival rates similar to those receiving ONCAB, OPCAB 
with IR was found to be significantly associated with a lower survival rate when 
compared to OPCAB and ONCAB with complete revascularization. It has been 
suggested that patients who undergo IR have multiple comorbidities and unfavorable 
anatomy that could bias the data in favour of complete revascularization [25]. However 
compelling evidence supports the hypothesis that diabetics are more likely to benefit 
from a more complete revascularization [26]. Raza et al. recently reported a long term 
survival analysis on 11922 diabetic patients [27] and they demonstrated that complete 
revascularization was associated with 10% lower late mortality. Moreover, they found 
that OPCAB was associated with 10% lower late mortality than ONCAB, but the 
difference was not statistically significant (P = 0.2). Nakano et al. [28] reported on 604 
consecutive patients underwent OPCAB during a 6-year period. A total of 216 patients 
  
 
had IR (13%), They found that all the event-free survival rates for all-cause mortality 
(P < .001), cardiac death (P = .020), and major adverse cardiac and cerebrovascular 
events (P < .001) were lower in the IR group. Of note, IR rate observed in the present 
OPCAB series was significantly lower than that reported by others. Omer at al. [29] 
recently reported a 29% rate of IR in 6367 OPCAB cases compared to 11.0% in 34,772 
ONCAB cases. Kleisli et al. [30] reported a 22% rate of IR in 207 OPCAB and 6.3% in 
827 ONCAB patients. Some have suggested that surgeon experience plays a role and 
emphasized the importance of surgeon volume in establishing favorable outcomes for 
OPCAB [24].The relatively low rate of IR in the present OPCAB series might partially 
related to the high OPCAB volume in our centre and support the hypothesis that when 
OPCAB is routinely performed, complete revascularization can be achieved in the 
majority of cases. Considering that the trend toward shorter survival with OPCAB 
observed in some studies may be related to incomplete revascularization [27,28], 
which seems more likely with less experienced surgeons with the technique, it is 
prudent to consider that OPCAB is not a surgery that should be performed routinely 
by any cardiac surgeon, but due to its beneficial potential in specific situations and in 
particular among diabetics, every surgeon should enable himself to perform it through 
proper training and use of specific available technology. Finally, although the use of 
additional grafts has been shown to minimize the risk related to incomplete 
revascularization [31], in the present series the rate of bilateral internal thoracic 
arteries usage has been particularly low (~2%) and this is partially due to the perceived 
increased vulnerability to sternal wound complication in this high risk cases [27].  
Limitations 
The main limitation of our study is that no follow-up data were available to compare 
the groups with respect to the cause of death (cardiac vs noncardiac), recurrence of 
  
 
angina, need for repeated revascularization, and graft patency. Therefore, we can only 
speculate about the mechanism beyond the equipoise between OPCAB and ONCAB 
on long-term survival. Finally, although the data were collected prospectively, the 
nonspecific design of the data for the analysis of the diabetic population limits the 
present analysis. Propensity technique can adjust only for measurable and included 
variables and we cannot exclude a selection bias based on non-measurable “eye-ball”. 
In conclusion, OPCAB is a safe and feasible option for diabetic patients with 
multivessel coronary disease. OPCAB reduces the incidence of postoperative 
complications and provides long term survival comparable to ONCAB strategy.  
Complete revascularization should still be the main goal while performing OPCAB 
surgery in diabetics. 
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Table 1. Pre-treatment variables distribution in the unmatched and matched OPCAB and ONCAB groups  1 
           
 
Unmatched 
OPCAB 
Unmatched 
OPCAB 
SMD PS-matched 
OPCAB 
PS-matched 
OPCAB 
SMD 
    n % n % 
 
n % n % 
 
Total sample            1253 100.0 1197 100.0 
 
995 100.0 995 100.0 
 
Age <60.0 307 24.5 282 23.6 4.8 242 24.3 233 23.4 2.4 
                        60-69 449 35.8 490 40.9 
 
360 36.2 393 39.5 
 
                        70-79 440 35.1 401 33.5 
 
346 34.8 345 34.7 
 
                         ≥8 57 4.5 24 2.0 
 
47 4.7 24 2.4 
 
    
          
Female                  No         976 77.9 929 77.6 0.7 765 76.9 762 76.6 0.7 
                        Yes        277 22.1 268 22.4 
 
230 23.1 233 23.4 
 
    
          
BMI <30 723 57.7 726 60.7 7.5 575 57.8 575 57.8 1.1 
                        ≥30 530 42.3 471 39.3 
 
420 42.2 420 42.2 
 
    
          
CCS                     No         654 52.2 526 43.9 16.5 514 51.7 491 49.3 4.6 
                        Yes        599 47.8 671 56.1 
 
481 48.3 504 50.7 
 
    
          
NYHA                    No         791 63.1 704 58.8 8.8 624 62.7 611 61.4 2.7 
                        Yes        462 36.9 493 41.2 
 
371 37.3 384 38.6 
 
    
          
MI within 30 days                   No    985 78.6 932 77.9 1.8 796 80.0 768 77.2 6.8 
                        Yes        268 21.4 265 22.1 
 
199 20.0 227 22.8 
 
    
          
PCI                     No         1157 92.3 1125 94.0 6.5 917 92.2 925 93.0 3.0 
                        Yes        96 7.7 72 6.0 
 
78 7.8 70 7.0 
 
    
          
DM on insulin                 No         733 58.5 706 59.0 0.9 583 58.6 584 58.7 0.2 
  
 
                        Yes        520 41.5 491 41.0 
 
412 41.4 411 41.3 
 
    
          
Current smoking                 No       1117 89.1 1060 88.6 1.8 889 89.3 888 89.2 0.3 
                        Yes        136 10.9 137 11.4 
 
106 10.7 107 10.8 
 
    
          
sCr>200mmol/l No         1204 96.1 1147 95.8 1.3 956 96.1 958 96.3 1.0 
                        Yes        49 3.9 50 4.2 
 
39 3.9 37 3.7 
 
    
          
COPD                    No          1140 91.0 1086 90.7 0.8 903 90.8 899 90.4 1.3 
                        Yes        113 9.0 111 9.3 
 
92 9.2 96 9.6 
 
    
          
CVA                     No         1179 94.1 1131 94.5 1.6 931 93.6 940 94.5 3.8 
                        Yes        74 5.9 66 5.5 
 
64 6.4 55 5.5 
 
    
          
PVD                     No         1075 85.8 991 82.8 8.2 853 85.7 848 85.2 1.4 
                         Yes        178 14.2 206 17.2 
 
142 14.3 147 14.8 
 
    
          
AF                      No         1198 95.6 1142 95.4 0.9 949 95.4 951 95.6 0.9 
                        Yes        55 4.4 55 4.6 
 
46 4.6 44 4.4 
 
    
          
TVD                     No         346 27.6 230 19.2 19.9 298 29.9 224 22.5 9.2 
                        Yes        907 72.4 967 80.8 
 
697 70.1 771 77.5 
 
    
          
LMD                      No         964 76.9 913 76.3 1.5 770 77.4 753 75.7 4.0 
                        Yes        289 23.1 284 23.7 
 
225 22.6 242 24.3 
 
    
          
LVEF<50% No         839 67.0 786 65.7 2.7 660 66.3 663 66.6 0.6 
                        Yes        414 33.0 411 34.3 
 
335 33.7 332 33.4 
 
    
          
LVEF 30-49% No 923 73.7 902 75.4 2.7 729 73.3 737 74.1 
 
  Yes 330 26.3 295 24.6 
 
266 26.7 258 25.9 
 
  
 
    
          
LVEF<30% No         1169 93.3 1081 90.3 10.9 926 93.1 921 92.6 1.9 
                         Yes        84 6.7 116 9.7 
 
69 6.9 74 7.4 
 
    
          
Cardiogenic shock                   No  1247 99.5 1178 98.4 10.9 990 99.5 990 99.5 0.0 
                        Yes        6 0.5 19 1.6 
 
5 0.5 5 0.5 
 
    
          
preop IABP               No         1237 98.7 1167 97.5 9.0 981 98.6 981 98.6 0.3 
                        Yes        16 1.3 30 2.5 
 
14 1.4 14 1.4 
 
    
          
non elective            No         644 51.4 560 46.8 9.2 520 52.3 476 47.8 8.8 
                        Yes        609 48.6 637 53.2 
 
475 47.7 519 52.2 
 
    
          
Emergent/salvage                No         1239 98.9 1171 97.8 8.3 982 98.7 980 98.5 1.7 
                        Yes        14 1.1 26 2.2 
 
13 1.3 15 1.5 
 
    
          
Era of surgery 1996-
2004 
398 31.8 306 25.6 34.6 254 25.5 256 25.7 9.8 
                        2005-
2007 
267 21.3 349 29.2 
 
273 27.4 276 27.7 
 
                        2008-
2010 
324 25.9 283 23.6 
 
240 24.1 269 27.0 
 
                        2011-
2015 
264 21.1 259 21.6 
 
228 22.9 194 19.5 
 
    
          
AdditiveEuroscore   4.2±2.6 
 
4.4±2.8 
  
4.2±2.7 
 
4.2±2.5 
  
    
          
Logistic Euroscore   5±5% 
 
5±7% 
  
5±5% 
 
4±5% 
  
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PS: propensity score; SMD: standardised 2 
mean difference; BMI: body mass index; CCS: Canadian cardiovascular class; NYHA: New York Heart Association; MI: myocardial 3 
  
 
infarction; PCI: percutaneous coronary intervention; DM diabetes mellitus; sCr: serum creatinine; COPD: chronic obstructive 4 
pulmonary disease; CVA: cerebrovascular accident; PVD: peripheral vascular disease; AF: atrial fibrillation; TVD: 3-vessel 5 
disease; LMD: left main disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump.  6 
  
 
Table 2. Intraoperative data 7 
 8 
          
 
OPCAB ONCAB P value 
  n % n %  
Overall   
 
1253 100.0 1197 100.0 
 
Number of grafts             1 36 2.9 6 0.5 <0.001 
          2 447 35.7 253 21.1 
 
          3 650 51.9 703 58.7 
 
          4 119 9.5 222 18.5 
 
          5 1 0.1 12 1.0 
 
  6 0 0.0 1 0.1 
 
  
      
Mean number of grafts/pt 
 
2.7±0.7 
 
3.0±0.7 
  
Graft target  
      
LAD       No 35 2.8 33 2.8 1 
          Yes 1218 97.2 1164 97.2 
 
  
      
DIA       No 1020 81.4 931 77.8 0.03 
          Yes 233 18.6 266 22.2 
 
  
      
CX        No 313 25.0 142 11.9 <0.001 
          Yes 940 75.0 1055 88.1 
 
  
      
RCA       No 398 31.8 305 25.5 <0.001 
          Yes 855 68.2 892 74.5 
 
  
      
RITA      No 1224 97.7 1160 96.9 0.3 
          Yes 29 2.3 37 3.1 
 
  
      
LITA      No 76 6.1 113 9.4 0.002 
          Yes 1177 93.9 1084 90.6 
 
  
      
BITA       No 1230 98.2 1163 97.2 0.1 
  
 
          Yes 23 1.8 34 2.8 
 
  
      
RA        No 986 78.7 1083 90.5 <0.001 
          Yes 267 21.3 114 9.5 
 
  
      
SV        No 137 10.9 58 4.8 <0.001 
          Yes 1116 89.1 1139 95.2 
 
  
      
sequential grafts No 1154 92.1 1150 96.1 <0.001 
          Yes 99 7.9 47 3.9 
 
LAD: left anterior descending artery; DIA: diagonal branch; CX: circumflex artery; RCA: right coronary artery; LITA: left interior 9 
thoracic artery; RITA: right interior thoracic artery; BITA: bilateral internal thoracic artery; RA: radial artery; SV: saphenous vein  10 
  
 
Table 3. Short term outcomes in the unmatched and matched OPCAB and ONCAB groups with relative effect size in the propensity 11 
score-matched population. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PS: propensity 12 
score; CVA: cerebrovascular event; RRT: renal replacement therapy; SWR: sternal wound reconstruction; IABP intra-aortic balloon 13 
pump) 14 
 15 
           unmatched 
OPCAB 
unmatched 
ONCAB 
PS-matched 
OPCAB 
PS-matched 
ONCAB 
PSM-adjusted 
estimate 
[95%CI] 
adjusted 
P 
  n % n % n % n %   
Sample size    1253 100.0 1197 100.0 995 100.0 995 100.0 
  
CVA No 1235 98.6 1167 97.5 983 98.8 971 97.6 0.49[0.25-0.99] 0.04 
        Yes 18 1.4 30 2.5 12 1.2 24 2.4 
  
    
          
RRT No 1193 95.2 1144 95.6 946 95.1 952 95.7 1.15[0.75-1.74] 0.52 
        Yes 60 4.8 53 4.4 49 4.9 43 4.3 
  
    
          
IABP No 1221 97.4 1136 94.9 969 97.4 942 94.7 0.48[0.30-0.77] 0.002 
        Yes 32 2.6 61 5.1 26 2.6 53 5.3 
  
    
          
SWR No 1240 99.0 1180 98.6 985 99.0 979 98.4 0.62[0.28-1.38] 0.24 
        Yes 13 1.0 17 1.4 10 1.0 16 1.6 
  
    
          
Re-exploration No 1224 97.7 1155 96.5 973 97.8 956 96.1 0.55[0.33-0.94] 0.02 
        Yes 29 2.3 42 3.5 22 2.2 39 3.9 
  
    
          
Any complication No 1118 89.2 1028 85.9 890 89.4 849 85.3 0.69[0.52-0.90] 0.005 
        Yes 135 10.8 169 14.1 105 10.6 146 14.7 
  
  
 
    
          
30-day mortality    No 1221 97.4 1171 97.8 970 97.5 976 98.1 1.32[0.73-2.40] 0.36 
        Yes 32 2.6 26 2.2 25 2.5 19 1.9 
  
    
          
IR No 1062 84.8 1102 92.1 865 86.9 921 92.6 2[1.50-2.7] <0.001 
        Yes 191 15.2 95 7.9 139 14.0 74 7.4 
  
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PS: propensity score; CVA: cerebrovascular 16 
event; RRT: renal replacement therapy; SWR: sternal wound reconstruction; IABP intra-aortic balloon pump 17 
  18 
  
 
Supplementary Table 1. Percentage of missing data  19 
BMI: body mass index; CCS: Canadian cardiovascular class; NYHA: New York Heart Association; MI: myocardial infarction; PCI: 20 
percutaneous coronary intervention; DM diabetes mellitus; sCr: serum creatinine; COPD: chronic obstructive pulmonary disease; 21 
CVA: cerebrovascular accident; PVD: peripheral vascular disease; AF: atrial fibrillation; TVD: 3-vessel disease; LMD: left main 22 
disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump.  23 
  
 
   
preoperative IABP 19.776 COPD 0.635 
sCr 19.518 CCS 0.622 
BMI 10.424 AF 0.622 
LMD 7.494 DMI 0.615 
MI30d 7.322 PCI 0.463 
TVD 1.984 shock 0.417 
CVA 1.508 non elective 0.093 
LVEF 1.27 emergent/salvage 0.093 
Current smoking 0.701 Age 0 
NYHA 0.688 Female 0 
PVD 0.661 Era of surgery 0 
  
 
  24 
  
 
Supplementary Table 2. Short term outcomes in patients with orally treated diabetes in the unmatched and matched OPCAB and 25 
ONCAB groups with relative effect size in the propensity score-matched population.  26 
           unmatched 
OPCAB 
unmatched 
ONCAB 
PS-matched 
OPCAB 
PS-matched 
ONCAB 
adjusted estimate 
[95%CI] 
adjusted P 
  n % n % n % n %   
Sample size    733 100.0 706 100.0 583 100.0 584 100.0 
  
CVA No 724 98.8 685 97.0 578 99.1 568 97.3 0.31[0.11-0.84] 0.02 
        Yes 9 1.2 21 3.0 5 0.9 16 2.7 
  
    
          
RRT No 706 96.3 683 96.7 562 96.4 565 96.7 1.11[0.592.09] 0.74 
        Yes 27 3.7 23 3.3 21 3.6 19 3.3 
  
    
          
IABP No 714 97.4 672 95.2 569 97.6 555 95.0 0.47[0.25-0.90] 0.02 
        Yes 19 2.6 34 4.8 14 2.4 29 5.0 
  
    
          
SWR No 728 99.3 696 98.6 579 99.3 575 98.5 0.44[0.14-1.44] 0.17 
        Yes 5 0.7 10 1.4 4 0.7 9 1.5 
  
    
          
Re-
exploration 
No 717 97.8 681 96.5 570 97.8 560 95.9 0.53[0.27-1.05] 0.07 
        Yes 16 2.2 25 3.5 13 2.2 24 4.1 
  
    
          
Any 
complication 
No 663 90.5 614 87.0 531 91.1 505 86.5 0.63[0.43-0.90] 0.01 
        Yes 70 9.5 92 13.0 52 8.9 79 13.5 
  
    
          
30-day 
mortality    
No 717 97.8 691 97.9 573 98.3 573 98.1 0.89[0.38-2.09] 0.78 
        Yes 16 2.2 15 2.1 10 1.7 11 1.9 
  
  
 
    
          
IR No 621 84.7 653 92.5 499 85.6 543 93.0 2.2[1.51-3.3] <0.001 
        Yes 112 15.3 53 7.5 84 14.4 41 7.0 
  
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PS: propensity score; CVA: cerebrovascular 27 
event; RRT: renal replacement therapy; SWR: sternal wound reconstruction; IABP intra-aortic balloon pump 28 
 29 
  30 
  
 
Supplementary Table 3. Short term outcomes in patients on insulin in the unmatched and matched OPCAB and ONCAB groups with 31 
relative effect size in the propensity score-matched population. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump 32 
coronary artery bypass; PS: propensity score; CVA: cerebrovascular event; RRT: renal replacement therapy; SWR: sternal wound 33 
reconstruction; IABP intra-aortic balloon pump) 34 
           unmatched 
OPCAB 
unmatched 
ONCAB 
PS-matched 
OPCAB 
PS-matched 
ONCAB 
adjusted 
estimate 
[95%CI] 
adjusted 
P 
  n % n % n % n %   
Sample size    520 100.0 491 100 412 100.0 411 100.0 
  
CVA No 511 98.3 482 98 405 98.3 403 98.1 0.87[0.31-2.42] 0.79 
        Yes 9 1.7 9 2 7 1.7 8 1.9 
  
    
          
RRT No 487 93.7 461 94 384 93.2 387 94.2 1.18[0.67-2.06] 0.57 
        Yes 33 6.3 30 6 28 6.8 24 5.8 
  
    
          
IABP No 507 97.5 464 95 400 97.1 387 94.2 0.48[0.24-0.98] 0.04 
        Yes 13 2.5 27 5 12 2.9 24 5.8 
  
    
          
SWR No 512 98.5 484 99 406 98.5 404 98.3 0.85[0.28-2.56] 0.77 
        Yes 8 1.5 7 1 6 1.5 7 1.7 
  
    
          
Re-
exploration 
No 507 97.5 474 97 403 97.8 396 96.4 0.59[0.26-1.36] 0.21 
        Yes 13 2.5 17 3 9 2.2 15 3.6 
  
    
          
Any 
complication 
No 455 87.5 414 84 359 87.1 344 83.7 0.77[0.54-0.99] 0.04 
        Yes 65 12.5 77 16 53 12.9 67 16.3 
  
  
 
    
          
30-day 
mortality    
No 504 96.9 480 98 397 96.4 403 98.1 1.81[0.77-4.28] 0.19 
        Yes 16 3.1 11 2 15 3.6 8 1.9 
  
    
          
IR No 441 84.8 449 91 357 86.7 378 92.0 1.76[1.12-2.8] 0.01 
        Yes 79 15.2 42 9 55 13.3 33 8.0 
  
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PS: propensity score; CVA: cerebrovascular 35 
event; RRT: renal replacement therapy; SWR: sternal wound reconstruction; IABP intra-aortic balloon pump  36 
  
 
Supplementary Table 4. Effect of off-pump coronary artery bypass (OPCAB) grafting over on-pump coronary artery bypass 37 
(ONCAB) grafting on outcomes of interest in a fully adjusted double robust analyisis.  38 
 
Effect size lower 95%CI upper 95%CI P 
Postoperative CVA 0.47* 0.23 0.97 0.04 
Postoperative RRT 1.23* 0.77 1.97 0.55 
Sternal wound reconstruction 0.35* 0.14 0.88 0.04 
Re-exploration for bleeding 0.57* 0.33 0.99 0.04 
Postoperative IABP 0.49* 0.3 0.82 0.009 
Any of above complication  0.7* 0.51 0.95 0.02 
Mortality at 30 days 1.4Ŧ 0.75 2.61 0.19 
Incomplete revascularization  2.41* 1.75 3.32 <0.0001 
Late mortality 1.09 Ŧ 0.91 1.29 0.55 
*Logistic regression model; Ŧ Cox regression model; CI: confidence interval 39 
CVA: cerebrovascular event; RRT: renal replacement therapy; IABP: intra-aortic balloon pump.  40 
 41 
 42 
  
 
 43 
Supplementary Table 5. Double robust analysis on postoperative cerebrovascular accident.  44 
  Effect Lower 
0.95CI 
Upper  
0.95CI 
OPCAB 0.47 0.23 0.97 
Age 1.25 0.71 2.18 
Female 1.17 0.51 2.67 
Body mass index 1.43 0.82 2.51 
Canadian Cardiovascular Class 0.7 0.32 1.5 
New Your Heart Association Class 1.29 0.59 2.8 
Myocardial Infarction  within 30 day 0.81 0.33 1.97 
Percutaneous Coronary intervention 1.26 0.39 4.01 
Diabetes Mellitus on insulin 1.03 0.5 2.11 
Current smoking 1.44 0.5 4.16 
Creatinine > 200 mmol/l 2.3 0.62 8.48 
Chronic Obstructive Pulmonary Disease 0.33 0.07 1.52 
Cerebrovascular accident 4.16 1.67 10.36 
Peripheral vascular disease 2.1 0.94 4.68 
Atrial fibrillation  0.65 0.08 5.02 
3-vessel disease 1.37 0.57 3.32 
Left main disease 1.61 0.75 3.43 
Left ventricular ejection fraction 30%-49% 0.62 0.27 1.46 
Left ventricular ejection fraction <30% 0.49 0.1 2.53 
Cardiogenic shock 4.5 0.26 76.93 
preop intraaortic balloon pump 2.75 0.47 16.09 
non elective 1.57 0.71 3.49 
emergent/salvage 2.76 0.4 18.91 
Era of surgery 1.81 1 3.28 
Bilateral internal thoracic arteries 2.21 0.26 18.59 
  
 
Radial artery 0.8 0.23 2.83 
Incomplete revascularization  1.01 0.33 3.06 
  45 
  
 
Supplementary Table 6. Double robust analysis on postoperative renal replacement therapy. 46 
  Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB 1.23 0.77 1.97 
Age 1.22 0.86 1.74 
Female 0.76 0.43 1.34 
Body mass index 1.27 0.92 1.74 
Canadian Cardiovascular Class 1.25 0.78 2.01 
New Your Heart Association Class 0.73 0.45 1.21 
Myocardial Infarction  within 30 day 0.66 0.36 1.2 
Percutaneous Coronary intervention 0.74 0.32 1.72 
Diabetes Mellitus on insulin 1.91 1.22 3 
Current smoking 0.98 0.45 2.11 
Creatinine > 200 mmol/l 5.24 2.65 10.35 
Chronic Obstructive Pulmonary Disease 0.66 0.31 1.41 
Cerebrovascular accident 2.11 1.04 4.27 
Peripheral vascular disease 1.47 0.85 2.53 
Atrial fibrillation  1.92 0.82 4.49 
3-vessel disease 0.89 0.53 1.48 
Left main disease 1.44 0.88 2.37 
Left ventricular ejection fraction 30%-49% 0.94 0.56 1.57 
Left ventricular ejection fraction <30% 1.26 0.56 2.86 
Cardiogenic shock 4.26 0.57 31.57 
preop intraaortic balloon pump 3.68 1.08 12.56 
non elective 1.05 0.64 1.72 
emergent/salvage 1.16 0.18 7.38 
Era of surgery 1.95 1.29 2.94 
Bilateral internal thoracic arteries 0.94 0.12 7.34 
Radial artery 0.76 0.36 1.61 
Incomplete revascularization  0.75 0.35 1.59 
 47 
  
 
 48 
 49 
Supplementary Table 7. Double robust analysis on need for intra-aortic balloon pump.  50 
  Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB 0.49 0.3 0.82 
Age 0.97 0.65 1.43 
Female 1.27 0.72 2.24 
Body mass index 0.82 0.6 1.11 
Canadian Cardiovascular Class 1.22 0.7 2.12 
New Your Heart Association Class 1.29 0.74 2.25 
Myocardial Infarction  within 30 day 1.68 0.91 3.1 
Percutaneous Coronary intervention 0.78 0.31 1.97 
Diabetes Mellitus on insulin 1.18 0.71 1.96 
Current smoking 0.24 0.07 0.84 
Creatinine > 200 mmol/l 2.5 1.03 6.09 
Chronic Obstructive Pulmonary Disease 0.65 0.26 1.66 
Cerebrovascular accident 0.3 0.04 2.24 
Peripheral vascular disease 0.77 0.38 1.55 
Atrial fibrillation  1.74 0.65 4.66 
3-vessel disease 0.91 0.5 1.65 
Left main disease 1.31 0.75 2.29 
Left ventricular ejection fraction 30%-49% 2.09 1.17 3.76 
Left ventricular ejection fraction <30% 8.3 4.32 15.93 
Cardiogenic shock 1.44 0.15 13.66 
preop intraaortic balloon pump 0.14 0.01 2.4 
non elective 0.87 0.48 1.57 
emergent/salvage 6.34 2.08 19.29 
  
 
Era of surgery 1.75 1.15 2.66 
Bilateral internal thoracic arteries 3.58 0.89 14.33 
Radial artery 0.36 0.11 1.2 
Incomplete revascularization  0.92 0.42 2.03 
Supplementary Table 8. Double robust analysis on risk of sternal wound reconstruction.  51 
  Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB 0.35 0.14 0.88 
Age 2.52 1.19 5.34 
Female 0.52 0.15 1.84 
Body mass index 2.23 0.97 5.11 
Canadian Cardiovascular Class 1.07 0.44 2.59 
New Your Heart Association Class 0.39 0.15 1.04 
Myocardial Infarction  within 30 day 0.43 0.13 1.43 
Percutaneous Coronary intervention 2.06 0.67 6.33 
Diabetes Mellitus on insulin 1.53 0.65 3.6 
Current smoking 0.81 0.16 3.97 
Creatinine > 200 mmol/l 4.56 1.26 16.52 
Chronic Obstructive Pulmonary Disease 3.62 1.4 9.39 
Cerebrovascular accident 0.68 0.08 5.56 
Peripheral vascular disease 0.61 0.17 2.18 
Atrial fibrillation  1.25 0.27 5.8 
3-vessel disease 0.33 0.13 1.01 
Left main disease 1.12 0.44 2.87 
Left ventricular ejection fraction 30%-49% 2.08 0.84 5.13 
Left ventricular ejection fraction <30% 2.95 0.75 11.67 
Cardiogenic shock - - - 
preop intraaortic balloon pump - - - 
non elective 1.3 0.51 3.34 
emergent/salvage - - - 
Era of surgery 2 0.7 5.72 
  
 
Bilateral internal thoracic arteries - - - 
Radial artery 2.07 0.62 6.93 
Incomplete revascularization  1.01 0.21 4.92 
  52 
  
 
Supplementary Table 9. Double robust analysis on risk of re-exploration for bleeding.  53 
 
Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB 0.57 0.33 0.99 
Age 0.98 0.64 1.5 
Female 1.1 0.59 2.06 
Body mass index 0.91 0.64 1.31 
Canadian Cardiovascular Class 1.35 0.74 2.44 
New Your Heart Association Class 0.55 0.29 1.03 
Myocardial Infarction  within 30 day 1.37 0.71 2.65 
Percutaneous Coronary intervention 0.33 0.08 1.44 
Diabetes Mellitus on insulin 0.93 0.53 1.64 
Current smoking 0.68 0.25 1.84 
Creatinine > 200 mmol/l 2.77 1.03 7.47 
Chronic Obstructive Pulmonary Disease 1.39 0.59 3.29 
Cerebrovascular accident 0.54 0.13 2.3 
Peripheral vascular disease 0.72 0.32 1.65 
Atrial fibrillation  2.18 0.8 5.94 
3-vessel disease 1.11 0.58 2.13 
Left main disease 0.7 0.37 1.33 
Left ventricular ejection fraction 30%-49% 0.72 0.37 1.4 
Left ventricular ejection fraction <30% 1.66 0.71 3.9 
Cardiogenic shock 13.13 1.66 104.09 
preop intraaortic balloon pump - - - 
non elective 2.54 1.31 4.93 
emergent/salvage 4.85 1.21 19.39 
Era of surgery 1.08 0.67 1.75 
Bilateral internal thoracic arteries 1.81 0.37 8.83 
Radial artery 0.36 0.11 1.2 
Incomplete revascularization  0.85 0.33 2.14 
 54 
  
 
  55 
  
 
Supplementary Table 10. Double robust analysis on incidence of any complication among cerebrovascular accident, renal 56 
replacement therapy, need for intraaortic balloon pump, sternal wound reconstruction and re-exploration for bleeding.  57 
  Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB  0.7 0.51 0.95 
Age  1.03 1.01 1.05 
Female  0.82 0.56 1.20 
Body mass index 1.03 1 1.06 
Diabetes mellitus on insulin 1.43 1.05 1.96 
Canadian Cardiovascular Class 1.08 0.77 1.50 
New Your Heart Association Class 0.84 0.6 1.19 
Myocardial Infarction  within 30 day 1.06 0.72 1.54 
Percutaneous Coronary intervention 1.11 0.64 1.85 
Current smoking 0.77 0.42 1.31 
Creatinine > 200 mmol/l 5.15 2.98 8.75 
Chronic Obstructive Pulmonary Disease 0.85 0.5 1.38 
Cerebrovascular accident 1.65 0.92 2.81 
Peripheral vascular disease 1.11 0.73 1.64 
Atrial fibrillation  1.27 0.63 2.34 
3-vessel disease 0.75 0.52 1.08 
Left main disease 1.47 1.05 2.06 
Left ventricular ejection fraction 30%-49% 1.3 0.91 1.83 
Left ventricular ejection fraction <30% 3.04 1.85 4.90 
Cardiogenic shock 0.85 0.13 4.38 
preop intraaortic balloon pump 1.43 0.44 3.88 
non elective 1.07 0.75 1.52 
emergent/salvage 4.72 1.8 11.81 
Era of surgery 1.65 1.14 2.41 
Bilateral internal thoracic arteries 1.27 0.72 2.37 
Radial artery 0.71 0.41 1.18 
  
 
Incomplete revascularization  1.05 0.62 1.71 
 58 
Supplementary Table 11. Double robust analysis on mortality within 30 days 59 
  Effect Lower 
0.95CI 
Upper 
0.95CI 
OPCAB 1.4 0.75 2.61 
Age 1.05 1.005 1.09 
Female 1.64 0.86 3.14 
Body mass index 0.81 0.55 1.2 
Canadian Cardiovascular Class 1.65 0.81 3.36 
New Your Heart Association Class 1.17 0.59 2.29 
Myocardial Infarction  within 30 day 1.01 0.48 2.13 
Percutaneous Coronary intervention 1.49 0.49 4.54 
Diabetes Mellitus on insulin 1.49 0.79 2.8 
Current smoking 0.24 0.03 1.78 
Creatinine > 200 mmol/l 1.03 0.23 4.54 
Chronic Obstructive Pulmonary Disease 0.59 0.17 1.99 
Cerebrovascular accident 1.5 0.52 4.32 
Peripheral vascular disease 1.54 0.74 3.18 
Atrial fibrillation  2.16 0.83 5.66 
3-vessel disease 1.39 0.62 3.14 
Left main disease 0.83 0.42 1.66 
Left ventricular ejection fraction 30%-49% 2.59 1.3 5.17 
Left ventricular ejection fraction <30% 3.79 1.54 9.32 
Cardiogenic shock 1.24 0.06 25.92 
preop intraaortic balloon pump 0.54 0.03 10.61 
non elective 2.25 1.04 4.86 
emergent/salvage 1.55 0.27 9 
Era of surgery 0.76 0.4 1.46 
  
 
Bilateral internal thoracic arteries 4.01 0.49 33.02 
Radial artery 0.35 0.08 1.51 
Incomplete revascularization  0.79 0.3 2.11 
 60 
 61 
 62 
Supplementary Table 12. Double robust analysis on incomplete revascularization. 63 
 64 
 Effect Lower 0.95 Upper 0.95 
OPCAB 2.41 1.75 3.32 
Age 1.17 0.92 1.49 
Female 1.4 1 1.96 
Body mass index 0.94 0.78 1.14 
Canadian Cardiovascular Class 0.87 0.63 1.2 
New Your Heart Association Class 1.18 0.85 1.65 
Myocardial Infarction  within 30 day 0.79 0.53 1.19 
Percutaneous Coronary intervention 0.66 0.35 1.21 
Diabetes Mellitus on insulin 0.99 0.73 1.35 
Current smoking 0.87 0.52 1.46 
Creatinine > 200 mmol/l 1.07 0.52 2.17 
Chronic Obstructive Pulmonary Disease 1.16 0.72 1.86 
Cerebrovascular accident 1.01 0.55 1.87 
Peripheral vascular disease 1.01 0.67 1.53 
Atrial fibrillation  0.95 0.48 1.91 
3-vessel disease 1.21 0.86 1.71 
Left main disease 1.19 0.85 1.67 
Left ventricular ejection fraction 30%-49% 0.99 0.55 1.77 
Left ventricular ejection fraction <30% 0.52 0.05 5.47 
Cardiogenic shock 1.14 0.35 3.68 
preop intraaortic balloon pump 1.18 0.84 1.64 
non elective 1.4 0.43 4.54 
  
 
emergent/salvage 1.48 1.13 1.93 
Era of surgery 1.48 0.5 4.41 
Bilateral internal thoracic arteries 0.21 0.13 0.35 
Radial artery 0.56 0.33 0.91 
 65 
  66 
  
 
Supplementary Table 13. Double robust analysis on late mortality. 67 
  Effect Lower 0.95 Upper 0.95 
OPCAB 1.09 0.91 1.29 
Age 1.06 1.04 1.07 
Female 0.92 0.76 1.12 
Body mass index 1.13 1.01 1.27 
Canadian Cardiovascular Class 1.02 0.84 1.23 
New Your Heart Association Class 1.06 0.87 1.28 
Myocardial Infarction  within 30 day 0.72 0.54 0.95 
Percutaneous Coronary intervention 1.02 0.66 1.59 
Diabetes Mellitus on insulin 1.18 1 1.4 
Current smoking 1.27 0.93 1.72 
Creatinine > 200 mmol/l 2.5 1.68 3.72 
Chronic Obstructive Pulmonary Disease 1.38 1.03 1.83 
Cerebrovascular accident 1.8 1.34 2.42 
Peripheral vascular disease 1.72 1.39 2.14 
Atrial fibrillation  1.82 1.32 2.52 
3-vessel disease 0.87 0.71 1.07 
Left main disease 1.1 0.9 1.35 
Left ventricular ejection fraction 30%-49% 1.31 1.08 1.59 
Left ventricular ejection fraction <30% 2.28 1.71 3.03 
Cardiogenic shock 0.48 0.09 2.44 
preop intraaortic balloon pump 1.2 0.39 3.7 
non elective 1.18 0.97 1.42 
emergent/salvage 1.13 0.53 2.41 
Era of surgery 0.91 0.66 1.23 
Bilateral internal thoracic arteries 0.87 0.43 1.77 
Radial artery 1.07 0.84 1.36 
Incomplete revascularization  1.49 1.15 1.92 
 68 
 69 
  
 
 70 
 71 
 72 
Supplementary Table 14. Person correlation coefficient and variance inflation factors (VIF) from the covariance matrix  73 
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 74 
OPCAB: off-pump coronary artery bypass; BMI: body mass index; CCS: Canadian cardiovascular class; NYHA: New York Heart 75 
Association; MI: myocardial infarction; PCI: percutaneous coronary intervention; DM diabetes mellitus; sCr: serum creatinine; 76 
COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; PVD: peripheral vascular disease; AF: atrial 77 
fibrillation; TVD: 3-vessel disease; LMD: left main disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump.  78 
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Figure Legend 80 
Figure 1. Number of off-pump coronary artery bypass (OPCAB) and on-pump coronary artery bypass (ONCAB) operations during 81 
the study period 82 
Figure 2. Survival curves in the unmatched and matched off-pump coronary artery bypass (OPCAB) and on-pump coronary artery 83 
bypass (ONCAB) groups.  84 
Figure 3. Survival curves in the matched off-pump coronary artery bypass (OPCAB) and on-pump coronary artery bypass (ONCAB) 85 
groups in patients with oral treatment and in patients on insulin 86 
Figure 4. Survival curves in the matched off-pump coronary artery bypass (OPCAB) and on-pump coronary artery bypass (ONCAB) 87 
groups in patients with complete (CR) and incomplete revascularization (IR) 88 
Central figure. Effect of off-pump coronary artery bypass (OPCAB) grafting over on-pump coronary artery bypass (ONCAB) grafting 89 
on outcomes of interest. (CVA: cerebrovascular event; RRT: renal replacement therapy; SW: sternal wound; IABP intra-aortic balloon 90 
pump) 91 
Supplementary Figure 1. Missing data and combinations overview. 92 
Supplementary Figure 2. Area under the curve (AUC) for propensity score.   93 
Video 1. Off-pump coronary artery bypass grafting technique at Bristol Heart Institute. 94 
